News | July 28, 2021
Torrent Pharmaceuticals Q1FY22 consolidated PAT up at Rs. 330 Cr
The company posted net profit of Rs.321 crores for the period ended June 30, 2020.
The company posted net profit of Rs.321 crores for the period ended June 30, 2020.
The company posted net profit of Rs.594.6 crores for the period ended June 30, 2020.
The company posted net profit of Rs.19.36 crores for the period ended June 30, 2020.
The company posted net loss of Rs.56.69 crores for the period ended June 30, 2020.
The company has decided to transfer our rights in relation to the lodex and Ostocalcium brands to GlaxoSmithKline Asia Private Limited
The US business faced price erosion due to increased competition.
The company is confident of commencing production at both Mahad and Chiplun units soon
It posted net (loss) of Rs.(34.13) crores for the period ended June 30, 2020.
The company proposes to utilise the net proceeds from the fresh issue towards payment of outstanding purchase consideration
The company confirms an upward revision to its 2021 Outlook, reflecting the expectation to achieve mid-teens CER sales growth
Subscribe To Our Newsletter & Stay Updated
